Atlas Venture Life Science Advisors LLC Lowers Stock Holdings in Kymera Therapeutics, Inc. $KYMR

Atlas Venture Life Science Advisors LLC reduced its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 4.8% during the 4th quarter, HoldingsChannel reports. The firm owned 4,659,874 shares of the company’s stock after selling 236,588 shares during the quarter. Kymera Therapeutics makes up approximately 41.9% of Atlas Venture Life Science Advisors LLC’s holdings, making the stock its biggest holding. Atlas Venture Life Science Advisors LLC owned approximately 0.06% of Kymera Therapeutics worth $362,585,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. US Bancorp DE grew its stake in shares of Kymera Therapeutics by 9.8% in the 3rd quarter. US Bancorp DE now owns 1,865 shares of the company’s stock valued at $106,000 after purchasing an additional 166 shares during the period. Larson Financial Group LLC grew its position in Kymera Therapeutics by 36.9% during the 4th quarter. Larson Financial Group LLC now owns 1,064 shares of the company’s stock worth $83,000 after acquiring an additional 287 shares during the last quarter. State Board of Administration of Florida Retirement System grew its position in Kymera Therapeutics by 3.3% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 12,655 shares of the company’s stock worth $985,000 after acquiring an additional 410 shares during the last quarter. Xponance LLC grew its position in Kymera Therapeutics by 13.1% during the 4th quarter. Xponance LLC now owns 4,505 shares of the company’s stock worth $351,000 after acquiring an additional 522 shares during the last quarter. Finally, Harbor Capital Advisors Inc. grew its position in Kymera Therapeutics by 2.2% during the 4th quarter. Harbor Capital Advisors Inc. now owns 30,573 shares of the company’s stock worth $2,379,000 after acquiring an additional 645 shares during the last quarter.

Analyst Ratings Changes

A number of research firms recently commented on KYMR. Jefferies Financial Group began coverage on Kymera Therapeutics in a research report on Monday, March 16th. They set a “buy” rating and a $110.00 price target on the stock. Stephens increased their price target on Kymera Therapeutics from $95.00 to $100.00 and gave the stock an “overweight” rating in a research report on Monday, March 2nd. Loop Capital set a $97.00 price target on Kymera Therapeutics in a research report on Monday. UBS Group increased their price target on Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $108.00 price target on shares of Kymera Therapeutics in a research report on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Kymera Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $117.14.

Insider Buying and Selling

In related news, insider Noah Goodman sold 8,264 shares of the firm’s stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $87.50, for a total transaction of $723,100.00. Following the sale, the insider owned 53,542 shares of the company’s stock, valued at approximately $4,684,925. This trade represents a 13.37% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Elena Ridloff sold 7,400 shares of the firm’s stock in a transaction on Tuesday, March 31st. The stock was sold at an average price of $85.37, for a total value of $631,738.00. The SEC filing for this sale provides additional information. Insiders have sold a total of 234,357 shares of company stock worth $19,072,496 over the last 90 days. 15.98% of the stock is currently owned by corporate insiders.

Kymera Therapeutics Stock Up 3.9%

KYMR stock opened at $86.21 on Friday. The business’s fifty day moving average is $82.85 and its 200-day moving average is $80.22. The company has a market cap of $7.09 billion, a P/E ratio of -24.15 and a beta of 2.02. Kymera Therapeutics, Inc. has a twelve month low of $36.65 and a twelve month high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. The company had revenue of $34.37 million for the quarter, compared to the consensus estimate of $8.27 million. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The firm’s quarterly revenue was up 55.5% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.82) EPS. Research analysts anticipate that Kymera Therapeutics, Inc. will post -3.25 earnings per share for the current fiscal year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.